Facebook 'Emotional Health' tool now available in India | WeForNews | Latest News, Blogs Facebook ‘Emotional Health’ tool now available in India – WeForNews | Latest News, Blogs
Connect with us

Health

Facebook ‘Emotional Health’ tool now available in India

On Mental Health Day on Saturday, Instagram launched a ‘The Real Talk’ content series in partnership with the Under25 community and The Artidote.

Published

on

Facebook

New Delhi, Oct 10 : Facebook on Saturday said its centralised resource centre called Emotional Health, launched this week to help people cope with growing mental health issues in the pandemic, is now available with locally relevant information from its Indian partners.

The partners in India are mental health campaign ‘OK to Talk’, iCALL Psychosocial Helpline (Tata Institute of Social Sciences), and The Live Love Laugh Foundation that will provide mental health helplines and resources catering to the local needs of users.

“Our Covid-19 Information Centre and Emotional Health, launched ahead of the Mental Health Day on the Facebook app, provides people with access to tips and information from leading experts,” said Ajit Mohan, Managing Director and Vice-President, Facebook India.

“We have also launched eight new wellbeing guides on Instagram, along with partners,” he said in a statement.

On Mental Health Day on Saturday, Instagram launched a ‘The Real Talk’ content series in partnership with the Under25 community and The Artidote.

It’s a three-part video series, hosted by the founder of The Artidote, Jovanny Ferreyra, a global mental health advocate.

“While mental health tools, resources and community guidelines are powerful and necessary components of making the social media experience a positive one, the majority of interaction still happens between members of a community,” Mohan said.

More than six million people in the Asia-Pacific region are part of over 35,000 active groups dedicated to mindfulness and mental well-being.

“Let’s be aware of our own emotions, and acknowledge the impact of this situation on our lives. Reach out for help, without hesitation and any inhibition,” Mohan added.

Blog

Global availability of Covid vaccine for public only by mid-2021: Moody’s

The report said mass vaccination that significantly reduces individual and public health concerns would lift sentiment and present a significant upside to global growth.

Published

on

By

Covid 19 Vaccine

New Delhi: While recent news about the high effectiveness of two coronavirus vaccines is a promising sign in the effort to combat the pandemic, a vaccine for Covid-19 will not be widely distributed before mid-2021, Moodys Investors Service said on Tuesday.

“However, these developments do not change the assumption underpinning our economic forecasts that widespread, global availability of the vaccine to the general public is only likely by around mid-2021,” Moody’s said in a report.

It added that the recent positive news about the effectiveness of vaccines under development will do little to ease the immediate concern that the current rise in coronavirus cases across the US and Europe will dampen sentiments and economic momentum in these regions this quarter and the next.

“Our baseline economic forecasts balance the downside risks of increasing infections and new lockdowns in the next two months, against the potential for widespread vaccinations over the next 12 months. If lockdowns are more severe than we expect, the negative effect on GDP could be offset if a coronavirus vaccine is available quicker and uptake is wider than we had expected,” it added.

Although successful Phase 3 trials of vaccines are a big step, there are numerous hurdles ahead, including satisfying approval requirements by regulators in individual countries, production of the billions of doses required for mass vaccination, ensuring proper storage and building distribution networks.

Distribution will likely occur in phases once regulators approve a vaccine, with health officials prioritizing access for healthcare workers and those in other high-risk professions, as well as for people who are most vulnerable to COVID-19, such as older people and individuals in care homes.

Moody’s said two important variables in overall success of vaccines in curbing the pandemic will be the public’s willingness to get vaccinated and what percentage of the population will need to be vaccinated in order for the spread of the virus to be brought under control. Vaccine availability likely will vary across countries, with cost and access major hurdles in particular for less-developed economies.

Many advanced and a handful of middle-income emerging market countries have already secured contracts for hundreds of millions of doses of the vaccines. Residents of these countries will be among the first to get the vaccinations, with their economies benefiting from the associated easing of the public health crisis. The earlier the health crisis in a country subsides, the stronger the country’s economic recovery will be, it added.

The report said mass vaccination that significantly reduces individual and public health concerns would lift sentiment and present a significant upside to global growth.

As long as the coronavirus remains a health risk, social distancing restrictions and the reluctance of consumers to engage in high contact social and economic activity will mar the recovery of services sectors. As vaccines become broadly available, health fears and concerns about an uncertain economic and financial outlook should recede, allowing for a quicker resumption of activity in high contact sectors such as hotels, restaurants, theaters, mass transit, airlines and travel and tourism.

Moody’s said the pandemic has already inflicted enormous damage on the hardest-hit sectors and will continue to undermine their financial condition and prospects, with repeated virus outbreaks and lockdown measures suppressing demand. The risk of business failure increases exponentially the longer the pandemic prevents a return to some semblance of normal activity.

A vaccine will help accelerate the recovery. But for many of these businesses, survival will remain challenging until the virus is no longer viewed as a significant public health threat. It is difficult to know how many businesses will survive several more months of below-normal revenue, it added.

Small and midsized businesses across advanced and emerging market countries are at risk and more of them will undoubtedly close on account of the prolonged cash flow shock. And those that do survive will have the long and arduous task of rebuilding their balance sheets while also, in many cases, facing significant changes in consumer behavior and demand patterns. “Therefore, even if economic activity returns to healthy levels once a vaccine is widely available, the detrimental economic impact and transformed operating environment will be felt for years to come”, Moody’s said.

Continue Reading

Health

Saudi Arabia to make COVID-19 vaccine free for citizens and residents

As per Gulf News, Dr Asiri told Al Ekhbariya that Saudi Arabia will receive vaccines through COVAX facility as well as through companies outside of the consortium.

Published

on

By

Saudi King Salman

Abu Dhabi: Saudi Arabia’s Health Ministry on Monday announced that it would make the coronavirus vaccine available for free to all citizens and residents.

“Those who have not tested positive for COVID-19 will be given priority in the vaccine campaign in the coming months,” said Dr Abdullah Asiri, the assistant undersecretary at the ministry.

He, however, added that those below 16 years of age will not be vaccinated unless research proves otherwise.

As per Gulf News, Dr Asiri told Al Ekhbariya that Saudi Arabia will receive vaccines through COVAX facility as well as through companies outside of the consortium.

“The Kingdom worked on two paths to obtain the vaccine, through the COVAX organisation, which the G20 had a role in creating and financing…Saudi Arabia will obtain a large number of vaccines through this facility, while the second track is directly contracting with the big companies to cover the gap that cannot be covered through COVAX,” Arab News mentioned Asiri as saying.

According to the World Health Organization, “the COVAX facility forms a key part of the COVAX pillar (COVAX) of the Access to COVID-19 Tools (ACT) Accelerator, a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.”

The Saudi Health Ministry further expected that by the end of next year, the vaccines would cover 70 per cent of the Kingdom’s population.

“One of the most important goals set by the G20 during Saudi Arabia’s G20 presidency is to support all-inclusive and equitable access to vaccines, diagnostic and treatment tools,” said Dr Abdullah Asiri.

Dr Asiri added that a comprehensive plan for vaccine distribution will be ready “in the coming weeks”.

During the two-day G20 summit hosted virtually in Riyadh, Dr Abdullah Al Rabeeah, the supervisor general of the King Salman Humanitarian Aid and Relief Centre, on Friday said that his country would be among the first ones to get hold of a COVID-19 vaccine.

Dr Al Rabeeah added that Saudi Arabia has spent over USD 200 million on COVID-19 vaccine and drug development.

Saudi King Salman bin Abdulaziz had in March also ordered free coronavirus treatment for all citizens.

Meanwhile, WHO director-general Tedros Adhanom Ghebreyesus on Monday announced: “There is now real hope that vaccines, in combination with other tried and tested public health measures, will help to end the pandemic.”

His remarks came after drugmaker AstraZeneca announced that its COVID-19 vaccine was up to 90 per cent effective. With this, AstraZeneca has become the third major drug company after Pfizer and Moderna to have reported late-stage data for a potential COVID-19 vaccine.

“The significance of this scientific achievement cannot be overstated. No vaccines in history have been developed as rapidly as these. The scientific community has set a new standard for vaccine development,” added Tedros.

Continue Reading

Health

One Crore Frontline Healthcare Workers To Receive Covid-19 Vaccine In First Leg

Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.

Published

on

covid-vaccine

An estimated one crore frontline health workers will receive the first dose of Covid-19 vaccine whenever it becomes available, with around 92 per cent of government hospitals and 55 per cent of private hospitals across all states and UTs providing data identifying the workers, official sources said.

Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.

States have been asked to accelerate the process of identifying frontline healthcare workers including doctors, MBBS students, nurses and ASHA workers etc, so that the exercise gets completed in another one week.

It has asked states to do planning and mapping of vaccination sessions where healthcare workers will be vaccinated during the 1st phase and mapping human resources across departments that could be deployed for vaccination sessions for verification of beneficiaries, crowd management and overall coordination.

Prime Minister Narendra Modi will meet with chief ministers and other representatives of states and union territories via video conferencing on Tuesday to discuss the vaccine distribution strategy, sources said.

“Around 92 per cent of all government hospitals and 55 per cent of all private hospitals from across all states and UTs have provided data. The rest of the details will come in another one week. We have asked the states to accelerate the process,” an official source said.

The anti-coronavirus vaccine, once available, would be distributed under a special Covid-19 inoculation programme, using the processes, technology and network of the existing Universal Immunisation Programme (UIP). It would run parallel to the UIP.

The Centre, with the help of state and UT governments, has started the process of identifying around 30 crore priority beneficiaries who would be given vaccine dose in the initial phase, sources had said.

The government has demarcated four categories which include around 1 crore healthcare professionals including doctors, MBBS students, nurses and ASHA workers etc, around two crore frontline workers including municipal corporation workers, personnel of the police and armed forces, about 26 crore people aged above 50 and a special category of those below 50 with co-morbidities and requiring specialised care.

Health Ministry’s existing digital platform eVIN which is being used for the UIP is being enhanced for the Covid-19 vaccine distribution and delivery, through which SMSs would be sent to recipients informing the time, date and venue to get the shots and digitally connect them and also track them, sources had earlier said.

Each person in the immunisation list would be linked with their Aadhar cards to avoid duplication and to track beneficiaries. However, in case a person doesn’t have an Aadhar card, a government photo identity can be used, the sources said.

Five vaccines are under different phases of clinical trials in India with the Serum Institute of India conducting phase-3 trial of the Oxford-Astrazeneca Covid-19 vaccine while the indigenously developed Bharat Biotech and ICMR vaccine has already started the phase III clinical trial.

Indigenously developed vaccine by Zydus Cadila has completed phase -2 clinical trial in the country.

Dr Reddy’s Laboratories will soon start combined phase 2 and 3 clinical trials of the Russian Covid-19 vaccine Sputnik V in India.Biological E. Ltd has started early phase 1 and 2 human trials of its Covid-19 vaccine candidate.

Union Health Minister Harsh Vardhan had said that a Covid-19 vaccine is likely to be available by the first quarter of 2021.

He had said that the Centre estimates to receive and utilise 40-50 crore doses of Covid-19 vaccine covering around 25 crore people by July next year.

“The prioritisation of groups for Covid-19 vaccine shall be based on two key considerations — occupational hazard and risk of exposure to infection, and the risk of developing severe disease and increased mortality,” he had said.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.